Shanghai Labway Clinical Laboratory Co (SZSE:301060) Cash-to-Debt : 2.15 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Shanghai Labway Clinical Laboratory Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai Labway Clinical Laboratory Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.15.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Shanghai Labway Clinical Laboratory Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Shanghai Labway Clinical Laboratory Co's Cash-to-Debt or its related term are showing as below:

SZSE:301060' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.67 Med: 3.24 Max: No Debt
Current: 2.15

During the past 9 years, Shanghai Labway Clinical Laboratory Co's highest Cash to Debt Ratio was No Debt. The lowest was 1.67. And the median was 3.24.

SZSE:301060's Cash-to-Debt is ranked better than
59.47% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.27 vs SZSE:301060: 2.15

Shanghai Labway Clinical Laboratory Co Cash-to-Debt Historical Data

The historical data trend for Shanghai Labway Clinical Laboratory Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Shanghai Labway Clinical Laboratory Co Cash-to-Debt Chart

Shanghai Labway Clinical Laboratory Co Annual Data

Trend

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

7.78

11.76

3.14

2.30

Shanghai Labway Clinical Laboratory Co Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															3.34	2.95	1.67	2.30	2.15

Competitive Comparison of Shanghai Labway Clinical Laboratory Co's Cash-to-Debt

For the Diagnostics & Research subindustry, Shanghai Labway Clinical Laboratory Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Labway Clinical Laboratory Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Labway Clinical Laboratory Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Shanghai Labway Clinical Laboratory Co's Cash-to-Debt falls into.

Shanghai Labway Clinical Laboratory Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Shanghai Labway Clinical Laboratory Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	861.201	/	(207.786	+	166.837)
	=	2.30

Shanghai Labway Clinical Laboratory Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	789.752	/	(206.735	+	160.979)
	=	2.15

Shanghai Labway Clinical Laboratory Co (SZSE:301060) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Shanghai Labway Clinical Laboratory Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Shanghai Labway Clinical Laboratory Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Labway Clinical Laboratory Co (SZSE:301060) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Shanghai Labway Clinical Laboratory Co Ltd (SZSE:301060) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 268, Linxin Road, Floor 6, 7, 8, 9 of Building 1, Changning District, Shanghai, CHN, 200335

Website

https://www.labway.cn

Labway Clinical Laboratory (Shanghai) Ltd provides comprehensive health management solutions relying on medical laboratory and pathological diagnosis services. It offers genetic testing, clinical microbiology testing, blood and pathology testing, cytopathological diagnosis and other services.

Executives

Sun Lin Jie

Director

Shanghai Labway Clinical Laboratory Co (SZSE:301060) Headlines

No Headlines